• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

异喹啉酮衍生物作为免疫蛋白酶体抑制剂的研究进展。

Development of isoquinolinone derivatives as immunoproteasome inhibitors.

机构信息

Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d'Alcontres, 31, 98166 Messina, Italy.

Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d'Alcontres, 31, 98166 Messina, Italy.

出版信息

Bioorg Med Chem Lett. 2022 Jan 1;55:128478. doi: 10.1016/j.bmcl.2021.128478. Epub 2021 Nov 24.

DOI:10.1016/j.bmcl.2021.128478
PMID:34838650
Abstract

The inhibition of immunoproteasome is considered nowadays a promising strategy for the treatment of hematologic malignancies. In this paper we report the design, synthesis, and biological evaluation as immunoproteasome inhibitors of a new series of isoquinolinone derivatives characterized by a (E)-prop-1-ene fragment that connects the heterocycle to a distal amide functionality. Among all the synthesized compounds, we identified an inhibitor with K values in the low micromolar or submicromolar range towards the chymotrypsin-like activities of both proteasome and immunoproteasome (β5c, β5i and β1i subunits). Molecular modeling studies suggest that the most potent compound of the series may act a single-site binder. In particular, through its isopentyl group, it might dock into P1 site in the case of the β1i catalytic subunit, while in the case of β5c and β5i subunits, the P3 site might be the preferred binding site.

摘要

目前,抑制免疫蛋白酶体被认为是治疗血液恶性肿瘤的一种有前途的策略。在本文中,我们报告了一系列新型异喹啉酮衍生物的设计、合成和作为免疫蛋白酶体抑制剂的生物学评价,这些衍生物的特点是具有将杂环与远端酰胺官能团连接的(E)-丙烯-1-基片段。在所合成的所有化合物中,我们鉴定出一种抑制剂,其对蛋白酶体和免疫蛋白酶体(β5c、β5i 和 β1i 亚基)的糜蛋白酶样活性的 K 值在低微摩尔或亚微摩尔范围内。分子建模研究表明,该系列中最有效的化合物可能是一种单一位点结合物。特别是,通过其异戊基部分,它可能在β1i 催化亚基的情况下结合到 P1 位,而在β5c 和β5i 亚基的情况下,P3 位可能是首选的结合位。

相似文献

1
Development of isoquinolinone derivatives as immunoproteasome inhibitors.异喹啉酮衍生物作为免疫蛋白酶体抑制剂的研究进展。
Bioorg Med Chem Lett. 2022 Jan 1;55:128478. doi: 10.1016/j.bmcl.2021.128478. Epub 2021 Nov 24.
2
Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors.鉴定2-硫代咪唑烷-4-酮衍生物为新型非共价蛋白酶体和免疫蛋白酶体抑制剂。
Bioorg Med Chem Lett. 2018 Feb 1;28(3):278-283. doi: 10.1016/j.bmcl.2017.12.053. Epub 2017 Dec 26.
3
Development of Novel Amides as Noncovalent Inhibitors of Immunoproteasomes.新型酰胺类免疫蛋白酶体非共价抑制剂的研发。
ChemMedChem. 2019 Apr 17;14(8):842-852. doi: 10.1002/cmdc.201900028. Epub 2019 Mar 26.
4
Development of peptide epoxyketones as selective immunoproteasome inhibitors.肽环氧酮类化合物作为选择性免疫蛋白酶体抑制剂的研究进展。
Eur J Med Chem. 2021 Oct 5;221:113556. doi: 10.1016/j.ejmech.2021.113556. Epub 2021 May 25.
5
Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.基于结构的人免疫蛋白酶体β1i 或 β5i 特异性抑制剂的设计。
J Med Chem. 2014 Jul 24;57(14):6197-209. doi: 10.1021/jm500716s. Epub 2014 Jul 15.
6
Virtual Screening Strategy and In Vitro Tests to Identify New Inhibitors of the Immunoproteasome.虚拟筛选策略及体外试验鉴定免疫蛋白酶体新型抑制剂
Int J Mol Sci. 2023 Jun 22;24(13):10504. doi: 10.3390/ijms241310504.
7
Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads.基于半胱氨酸和苏氨酸的片段大小和双齿(免疫)蛋白酶体抑制剂靶向弹头。
Cells. 2021 Dec 6;10(12):3431. doi: 10.3390/cells10123431.
8
Identification of N, C-capped di- and tripeptides as selective immunoproteasome inhibitors.鉴定 N、C 端封端的二肽和三肽作为选择性免疫蛋白酶体抑制剂。
Eur J Med Chem. 2022 Apr 15;234:114252. doi: 10.1016/j.ejmech.2022.114252. Epub 2022 Mar 8.
9
Immunoproteasome β5i-Selective Dipeptidomimetic Inhibitors.免疫蛋白酶体β5i选择性二肽模拟物抑制剂
ChemMedChem. 2016 Oct 6;11(19):2127-2131. doi: 10.1002/cmdc.201600384. Epub 2016 Aug 25.
10
Structure-Based Design of Fluorogenic Substrates Selective for Human Proteasome Subunits.基于结构的人蛋白酶体亚基选择性荧光底物设计。
Chembiochem. 2020 Nov 16;21(22):3220-3224. doi: 10.1002/cbic.202000375. Epub 2020 Jul 29.

引用本文的文献

1
Drug Combination Studies of Isoquinolinone AM12 with Curcumin or Quercetin: A New Combination Strategy to Synergistically Inhibit 20S Proteasome.异喹啉酮 AM12 与姜黄素或槲皮素的药物联合研究:协同抑制 20S 蛋白酶体的新联合策略。
Int J Mol Sci. 2024 Oct 4;25(19):10708. doi: 10.3390/ijms251910708.
2
Virtual Screening Strategy and In Vitro Tests to Identify New Inhibitors of the Immunoproteasome.虚拟筛选策略及体外试验鉴定免疫蛋白酶体新型抑制剂
Int J Mol Sci. 2023 Jun 22;24(13):10504. doi: 10.3390/ijms241310504.
3
Chemoselective cycloisomerization of O-alkenylbenzamides via concomitant 1,2-aryl migration/elimination mediated by hypervalent iodine reagents.
通过高价碘试剂介导的伴随1,2-芳基迁移/消除反应实现O-烯基苯甲酰胺的化学选择性环异构化反应。
Commun Chem. 2023 Jun 17;6(1):126. doi: 10.1038/s42004-023-00930-5.